MicuRx Pharmaceuticals
Clinical-stage biopharmaceutical company (founded 2007) focused on discovery, development, and commercialization of novel therapeutics for infectious diseases and select kidney indications. Operates R&D centers in China and the US and pursues China–US parallel development, with an integrated development system spanning early design, preclinical evaluation, global clinical development, manufacturing management, and regulatory affairs.
Industries
Nr. of Employees
medium (51-250)
MicuRx Pharmaceuticals
Products
Contezolid (oxazolidinone antibiotic)
Next-generation oxazolidinone-class antibacterial agent developed for treatment of multidrug-resistant Gram-positive infections; developed for oral administration and evaluated across Phase I–III clinical studies and included in national reimbursement listing.
Injectable prodrug for oxazolidinone (water-soluble prodrug enabling IV→oral sequence)
Injectable prodrug designed to convert in vivo to an oxazolidinone active compound to enable IV administration followed by oral therapy in sequential regimens.
Polymyxin-class antibiotic development for MDR Gram-negative infections
Development of next-generation polymyxin-class agents targeting carbapenem-resistant and other multidrug-resistant Gram-negative pathogens.
Oral antibacterial candidate for non-tuberculous mycobacterial (NTM) infections
Novel small-molecule agent in development for NTM pulmonary disease, evaluated in Phase I and advanced to later-stage clinical development with regulatory designations.
Kidney-targeted therapeutic candidates
Chemically modified drug entities designed for targeted distribution to the kidney to increase local drug concentration while reducing systemic exposure.
Monoclonal antibody–drug conjugate (ADC) candidate
Next-generation ADC targeting tumors using optimized camptothecin-based payload and linker chemistry.
Contezolid (oxazolidinone antibiotic)
Next-generation oxazolidinone-class antibacterial agent developed for treatment of multidrug-resistant Gram-positive infections; developed for oral administration and evaluated across Phase I–III clinical studies and included in national reimbursement listing.
Injectable prodrug for oxazolidinone (water-soluble prodrug enabling IV→oral sequence)
Injectable prodrug designed to convert in vivo to an oxazolidinone active compound to enable IV administration followed by oral therapy in sequential regimens.
Polymyxin-class antibiotic development for MDR Gram-negative infections
Development of next-generation polymyxin-class agents targeting carbapenem-resistant and other multidrug-resistant Gram-negative pathogens.
Oral antibacterial candidate for non-tuberculous mycobacterial (NTM) infections
Novel small-molecule agent in development for NTM pulmonary disease, evaluated in Phase I and advanced to later-stage clinical development with regulatory designations.
Kidney-targeted therapeutic candidates
Chemically modified drug entities designed for targeted distribution to the kidney to increase local drug concentration while reducing systemic exposure.
Monoclonal antibody–drug conjugate (ADC) candidate
Next-generation ADC targeting tumors using optimized camptothecin-based payload and linker chemistry.
Expertise Areas
- Anti-infective small-molecule discovery
- Clinical trial management (Phase I–III)
- Preclinical pharmacology and toxicology
- Regulatory strategy and submissions (IND/NDA, expedited pathways)
Key Technologies
- Medicinal chemistry
- Prodrug design (IV and oral)
- Renal-targeted drug delivery chemistry
- Antibody–drug conjugation and linker chemistry
News & Updates
U.S. FDA cleared an IND enabling initiation of a multicenter Phase 2a trial in adults with Mycobacterium abscessus pulmonary disease.
U.S. FDA granted orphan drug designation for an oral agent targeting non-tuberculous mycobacterial infections.
Successful completion of a Phase III trial evaluating an injectable prodrug followed by oral therapy for complex skin and soft tissue infections; primary efficacy endpoint achieved.
Phase I study completed evaluating safety, tolerability, pharmacokinetics and food effect of an oral antibacterial candidate; results supported further development.
Company presented 15 clinical and preclinical research datasets related to its pipeline (focused on oxazolidinone and NTM candidates) at a major infectious diseases conference.
National medical regulatory approval obtained and the oral oxazolidinone product included in the national reimbursement drug list in China; listing subsequently renewed.
U.S. FDA cleared an IND enabling initiation of a multicenter Phase 2a trial in adults with Mycobacterium abscessus pulmonary disease.
U.S. FDA granted orphan drug designation for an oral agent targeting non-tuberculous mycobacterial infections.
Successful completion of a Phase III trial evaluating an injectable prodrug followed by oral therapy for complex skin and soft tissue infections; primary efficacy endpoint achieved.
Phase I study completed evaluating safety, tolerability, pharmacokinetics and food effect of an oral antibacterial candidate; results supported further development.
Company presented 15 clinical and preclinical research datasets related to its pipeline (focused on oxazolidinone and NTM candidates) at a major infectious diseases conference.
National medical regulatory approval obtained and the oral oxazolidinone product included in the national reimbursement drug list in China; listing subsequently renewed.